Drugs in Dev. Neurology
Phase I/ Phase II
Canada 
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ketarx™ (ketamine hydrochloride), is a non-barbiturate, rapid-acting general anesthetic and NMDA receptor antagonist used for induction of anesthesia diagnostic and surgical procedures typically in combination with a muscle relaxant in patients with pa...
Product Name : Ketarx
Product Type : Controlled Substance
Upfront Cash : Inapplicable
February 05, 2023
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The data highlight that ketamine was safe, well-tolerated, and demonstrated that 100% of subjects treated with ketamine had reduction in dyskinesias indicating possible efficacy with a large effect size that warrants further investigation in a pivotal Ph...
Product Name : Ketarx
Product Type : Controlled Substance
Upfront Cash : Inapplicable
November 14, 2022
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Alcami
Deal Size : Undisclosed
Deal Type : Agreement
PharmaTher Engages Alcami for Clinical and Commercial Manufacturing of Novel Ketamine Products
Details : PharmaTher is evolving to become a leader in ketamine-based solutions for mental health, neurological and pain disorders, and partnering with Alcami as our exclusive manufacturer for the clinical and commercial supply of ketamine.
Product Name : Ketarx
Product Type : Controlled Substance
Upfront Cash : Undisclosed
October 19, 2021
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Alcami
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Galantamine Benzoate
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ALPHA-1062 is proprietary, delayed release tablet formulation designed to treat Alzheimer’s disease is being developed as a new generation of AChEI designed to improve existing therapy by overcoming gastrointestinal side effects and tolerability limita...
Product Name : Alpha-1062
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 09, 2021
Lead Product(s) : Galantamine Benzoate
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Galantamine Benzoate
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Alpha Cognition, Inc. Receives FDA/PMDA Regulatory Guidance for Alpha-1062 Alzheimer's Therapy
Details : U.S. FDA agreed upon a clinical and regulatory pathway for the approval of Alpha-1062 and has suggested that a single pivotal trial, scheduled for mid-2021.
Product Name : Alpha-1062
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 30, 2020
Lead Product(s) : Galantamine Benzoate
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
